PFS of this case taking darafenib plus trametinib was 5 months, which is much lower than the median PFS in previous clinical trial (10.9 mo) enrolling patients with untreated BRAF V600E-mutant metastases.[19] The fact that this case responded poorly to darafenib plus trametinib but well to alectinib, indicating that ALK activation, rather than BRAF V600E, is the main driver factor of lung cancer when they coexist. Here, BRAF is linked to lung carcinoma.